#USA #New York #Class Action #Pomerantz Law Firm #Vistagen Therapeutics

Investor Alert: Pomerantz Law Firm and Class Action Against Vistagen Therapeutics

In a significant development for investors, Pomerantz LLP has made a formal announcement regarding a class action lawsuit filed against Vistagen Therapeutics, Inc., a company operating under the NASDAQ ticker symbol VTGN. This lawsuit comes in the wake of substantial losses experienced by investors following recent events concerning the company's clinical trials.

Details of the Class Action

Investors who purchased or otherwise acquired Vistagen securities during the designated class period are encouraged to take note of this lawsuit. Specifically, they have until March 16, 2026, to petition the court for the appointment as Lead Plaintiff if they have suffered financial losses due to the company's alleged fraudulent actions. For those looking to join the lawsuit, details on how to proceed can be found by contacting Pomerantz directly or accessing their official website.

The crux of the allegations revolves around claims that Vistagen, along with certain officers and directors, engaged in unlawful business practices that misled investors regarding the company's operations and prospects. Investors who feel they have been impacted by such actions are strongly advised to act swiftly to protect their interests.

The Trigger Event

A critical moment that contributed to this situation occurred on December 17, 2025, when Vistagen released a press statement regarding the PALISADE-3 Phase 3 study of its drug fasedienol, intended for treating social anxiety disorder. The study results were disappointing, revealing that there was no significant improvement on the primary endpoint. This announcement led to a dramatic decline in Vistagen's stock price, which plummeted by over 80%, closing at just $0.861 per share as investors reacted negatively to the news.

Such events have undoubtedly drawn the attention of investors and regulatory bodies alike. The sudden drop following the disclosure of these trial results highlights the risks associated with investing in biotechnology and pharmaceutical sectors, where the success of products can significantly alter a company’s financial stability.

About Pomerantz LLP

Pomerantz LLP stands as a well-respected firm known for its expertise in corporate, securities, and antitrust class litigation. Having established a reputation over 85 years ago, the firm, founded by Abraham L. Pomerantz, has fought diligently for the rights of investors victimized by securities fraud and corporate improprieties. Through persistent legal efforts, Pomerantz has secured multimillion-dollar settlements for countless clients.

Potential class members with inquiries about the case are urged to reach out to Danielle Peyton at Pomerantz LLP via phone or email. Inquiries can be submitted with preferred contact information and the number of shares purchased to facilitate the proceedings.

Conclusion

As the landscape of Vistagen Therapeutics continues to evolve following this lawsuit, investors impacted by recent disclosures should remain vigilant and well-informed. With deadlines approaching, now is the time for any affected individuals to explore their legal rights and the possibility of claiming damages against the company. For more information, interested parties can find all necessary details regarding the class action and participate in the ongoing legal developments surrounding Vistagen Therapeutics.